100% Tariffs on Pharma Imports. Your Formulation Has 120 Days.

The 120 Day Clock

On 2 April 2026, the one year anniversary of "Liberation Day," the Trump administration signed an executive order imposing tariffs of up to 100% on patented pharmaceutical imports under Section 232 of the Trade Expansion Act of 1962. The order covers all patented pharmaceutical articles listed in the FDA Orange Book or Purple Book, their active pharmaceutical ingredients, and key starting materials. For the 17 largest pharmaceutical companies named in Annex III, the tariffs take effect in 120 days. For everyone else, 180 days.

The legal basis is a year long Department of Commerce investigation that concluded pharmaceutical imports threaten to "impair the national security of the United States." The numbers behind that finding: approximately 53% of patented pharmaceutical products and 85% of patented APIs by volume are produced abroad, with only 11% of API manufacturers based in the United States. The resulting executive order creates a graduated system that rewards pharmaceutical companies willing to match global pricing and reshore manufacturing while punishing those that do not comply. Combined pharmaceutical investment pledges from industry now exceed $480 billion. The question is whether the supply chain can actually move that fast, and what happens to your formulation when it does.

The implications reach far beyond trade policy. When your API source changes country, your formulation changes. Different synthesis routes yield different polymorphs, particle sizes, and impurity profiles. Every manufacturing site transfer triggers re validation, potentially bioequivalence studies, and regulatory supplements that consume years. The tariff clock runs on political time. Pharmaceutical technology runs on science time. The gap between the two is where billions of dollars in pharmaceutical investment and patient access hang in the balance.

Rates, Exemptions, and the MFN Framework

The executive order establishes a tiered tariff structure with multiple pathways to reduced rates. The default is 100% on all patented pharmaceuticals and APIs unless a lower rate applies.

The 0% rate for companies that sign both an onshoring commitment and a Most Favoured Nation pricing agreement is the central mechanism. It provides immediate tariff relief in exchange for pledges to reshore manufacturing and match global drug pricing. But the relief expires 20 January 2029, and the onshoring only rate of 20% escalates to 100% by 2 April 2030, if no MFN deal is reached. The structure creates a series of escalating deadlines layered on top of each other, each one tighter than the last.

The covered products include patented pharmaceutical articles subject to unexpired U.S. patents, plus associated active pharmaceutical ingredients and key starting materials. The tariff order followed the Supreme Court's 20 February 2026 ruling in Learning Resources, Inc. v. Trump, which struck down "reciprocal" tariffs imposed under IEEPA as unconstitutional. Section 232 tariffs, authorised under the Trade Expansion Act of 1962, were explicitly not affected by that ruling. The administration shifted legal footing, not policy direction.

Of the 17 pharmaceutical companies that received MFN letters, 16 have signed deals. Pfizer signed first, in September 2025, committing $70 billion to U.S. R&D and manufacturing. Eli Lilly followed with $27 billion in new manufacturing across four sites. Novo Nordisk committed $10 billion including end to end U.S. production of Wegovy tablet. Nine companies signed simultaneously in December 2025: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, EMD Serono, Genentech, Gilead Sciences, GSK, and Sanofi. Johnson & Johnson ($55 billion), AbbVie ($100 billion over 10 years), Novartis ($23 billion over five years), and Merck ($70 billion total) signed in January 2026. Regeneron remains the sole holdout, though analysts expect a deal announcement imminently.

Company by Company Breakdown

The scale of the reshoring commitment is staggering. Fourteen companies have pledged over $480 billion in combined U.S. pharmaceutical investment over four to ten year horizons, encompassing 22 new manufacturing sites and more than 44,000 projected jobs.

Beyond the big pharma signatories, the order is pulling in secondary investment. BD announced $110 million to expand glass prefillable syringe production in Columbus, Nebraska, addressing a critical but overlooked link in pharmaceutical logistics: the container closure systems that biologics depend on. South Korea's Celltrion acquired Eli Lilly's biologics facility in Branchburg, New Jersey for $330 million, then committed an additional $478 million to upgrade the plant, bringing total bioreactor capacity to 132,000 litres. These moves signal that the reshoring wave extends across the full pharmaceutical supply chain, from active ingredients to the syringes that deliver them.

Tariffs will undermine this important goal... every dollar spent on tariffs is a dollar that can't go toward the $400 billion in capital investments companies have announced.

Stephen Ubl, President and CEO, PhRMA

When Your API Source Changes Country, Your Formulation Changes

Trade policy ignores this reality, and no amount of pharmaceutical investment can shortcut it. When a pharmaceutical company changes its API supplier, whether due to tariffs, geopolitics, or supply disruption, the downstream formulation consequences are severe. The molecule stays the same, but the polymorph, particle size, impurity profile, and dissolution behaviour all shift.

Polymorph variability

An API synthesized via a different route may crystallise into a different polymorphic form. The same molecule in a different crystal lattice exhibits different solubility, dissolution rate, and bioavailability. A drug that is chemically identical to the reference listed drug but possesses different physical properties can, as DrugPatentWatch puts it, "significantly impact the final drug product's dissolution profile and bioavailability, potentially leading to a failed bioequivalence study and a catastrophic delay in ANDA approval."

Particle size distribution

Different milling equipment, different atmospheric conditions, and different supplier specific processes all produce APIs with different d10, d50, and d90 distributions. For BCS Class II and IV drugs, where solubility is the rate limiting step, particle size directly governs dissolution and absorption. A domestic API supplier running different micronisation equipment will produce material that behaves differently in the same tablet press with the same compression parameters.

Impurity profiles

Different synthesis routes produce different impurity profiles, which may require new analytical methods, revised specifications, and updated stability studies. A pharmaceutical company sourcing an API from a new location must evaluate the impurity profile and stability data compared to the previous source. The impurities are not interchangeable, and regulatory filings are built around specific impurity specifications tied to specific manufacturing processes.

Excipient sourcing disruption

The tariff order covers not just APIs but "associated pharmaceutical ingredients and key starting materials." Excipient supply chains are equally globalised. Changes to filler, binder, or coating suppliers can alter tablet hardness, disintegration, and ultimately drug release kinetics. The formulation is an integrated system. Changing one input changes the system.

• Every new domestic API supplier must be qualified through full characterisation: polymorph screening, particle size analysis, impurity profiling, forced degradation studies, and comparative dissolution testing.
• Manufacturing processes validated for one site do not automatically transfer. Equipment differences, water systems, HVAC, and local humidity affect process performance.
• New site means new stability data. ICH stability studies require 6 months accelerated and 12 months long term data minimum before regulatory submission.
• For significant changes, in vivo bioequivalence studies may be required, adding 9 to 18 months to the timeline.
• Prior Approval Supplements for site changes require comprehensive documentation and FDA review with inspection, a 6 to 18 month process.

$19.7 Billion to $23 Billion in New Costs

The Tax Foundation estimates pharmaceutical tariffs would increase costs between $19.7 billion and $23 billion in 2026 under narrow versus maximal application. Under Section 232 as structured, the tariffs are projected to raise $81 billion in revenue. Ernst & Young projects that even a 25% tariff on pharmaceutical imports could increase national drug costs by almost $51 billion per year. Even where tariffs are narrowly targeted and regulations prevent firms from passing costs directly to consumers, they "will act as a hidden cost on Americans: they would shrink incomes, reduce investment, and lead to less innovation."

The generic drug exemption is the critical buffer. Generic drugs represent 90% of all U.S. prescriptions but only 12 to 13% of total drug spending. Generics and biosimilars together saved the U.S. healthcare system $467 billion in 2024. The current exemption keeps that system intact, but the executive order directs the Secretary of Commerce to review the exemption within one year. That review clause injects uncertainty into the single largest source of affordable medication in the country.

Brookings senior fellow Marta Wosinska provides the sharpest analysis of how tariffs will flow through different market segments. For branded drugs, price increases are likely but constrained by inflation rebates, competitive dynamics, and political considerations. For generic drugs, the worry is the opposite: "My big worry on the generic side is that we actually won't see prices increase enough... and as a result, manufacturers are just going to walk away." Generic manufacturers operate on thin margins, and GPO contracts running one to three year terms limit the ability to pass through costs. Sterile injectable generics are the highest risk category. Forty two percent are U.S. produced but still vulnerable to API tariffs, and these markets are "particularly slow to adjust to supply shocks."

India and China: The Real Supply Chain

India supplies approximately 47% of U.S. generic prescriptions by volume and nearly 80% of all generic tablets and capsules. India produces roughly 35% of the world's APIs. The current tariff exemption for generics shields Indian pharmaceutical sales to the U.S. from immediate impact, but the one year review clause makes that protection temporary.

The deeper vulnerability sits upstream. China controls over 80% of the global market for key starting materials and intermediates used in API manufacturing. India depends on China for approximately 70% of its bulk drug and intermediate imports and up to 90% for critical antibiotics including cephalosporins and penicillin. Building a new API plant in India or the United States does not fully de risk the supply chain if key starting materials still come from China. Pharmaceutical raw materials flow through a dependency chain that tariffs on finished products do not address.

The Strait of Hormuz crisis compounds the pressure. The U.S. Israel Operation Epic Fury, launched 28 February 2026, has effectively halted 90% of commercial shipping through the strait as of 16 March. India depends on the strait for approximately 40% of crude oil imports, and petrochemical derivatives are critical inputs for API synthesis. Global air cargo capacity dropped 79% in the Gulf region within days of the operation's launch. API prices in India have spiked: paracetamol API rose from INR 220 to 240 per kilogram to INR 550 to 600; thiocolchicoside API doubled. Shipping insurance premiums surged over 1,000% for Hormuz transit. The estimated cost to India's pharmaceutical sector is INR 2,500 to 5,000 crore ($300 to $600 million) in export disruption.

China's December 2024 removal of the 13% export tax rebate for chemically modified oils and other inputs has already permanently raised the cost structure of Chinese APIs. Combined with tariff pressure and the Hormuz crisis, the pharmaceutical industry faces a triple supply chain shock that hits pharmaceutical logistics at every tier.

Tariffs, MFN pricing, and an uncertain policy environment work against goals of business expansion in the U.S. The risks are acute for small and mid-size biotech companies that often lack the capital to build dedicated manufacturing.

John Crowley, President and CEO, BIO

Meanwhile, all 16 pharmaceutical companies that signed MFN deals still raised some list prices for 2026. Pharmaceutical companies raised list prices on 872 brand name medications in January 2026, with a median increase of 4%, up from 250+ drugs at the same point the prior year. The MFN deals mainly impact Medicaid and cash paying customers through the TrumpRx.gov portal; private insurance and Part D pricing remain largely unaffected. Insurers are already pricing tariff risk into premiums: UnitedHealthcare of New York built a 3.6% increase into rate filings; Independent Health Benefits Corporation of New York added 2.9%. Of 88 small group market rate filings reviewed, one quarter explicitly cited tariffs as a cost driver.

The innovation numbers are equally concerning. Venture capital funding for small molecule R&D has fallen by nearly 70% since 2021. Clinical trial starts for new small molecule medicines decreased by 25%. Clinical trials for new uses of existing medicines fell 30 to 45%. The MFN pricing pressure and tariff uncertainty are suppressing the exact kind of pharmaceutical investment that the reshoring agenda claims to encourage.

Three to Five Years of Work, 120 Days to Start

Building pharmaceutical manufacturing capacity is a three to five year process at minimum. Permitting and construction take two to three years. Equipment qualification (IQ/OQ/PQ) takes 6 to 12 months. Process validation runs 3 to 6 months per product. FDA pre approval inspection adds 3 to 6 months. Regulatory supplement review for Prior Approval Supplements takes 6 to 18 months. Infrastructure costs range from $1 billion to $23 billion per facility depending on scale and technology. The skilled workforce needed to operate these facilities is concentrated in a handful of U.S. hubs: Research Triangle Park in North Carolina, Greater Indianapolis in Indiana, and the Boston Cambridge corridor in Massachusetts.

The administration's answer to this timing mismatch is the MFN pricing deal: sign now, build later, pay 0% in the interim. The onshoring commitment is a pledge, not a delivered factory. The tariff relief is immediate; the manufacturing buildout is aspirational. RBC Capital Markets identified the core tension: three year policy certainty against twenty year investment decisions creates potential stranded costs if future administrations reverse course. Pharmaceutical companies are committing tens of billions in pharmaceutical investment against a policy that expires 20 January 2029. The deals are voluntary, unlike the IRA's statutory Medicare negotiations, and can be renegotiated or abandoned.

For smaller biotech companies without the capital to build U.S. facilities, the 180 day timeline is equally untenable. BIO's John Crowley calls this the central vulnerability: the policy creates a two tier pharmaceutical market where only the largest pharmaceutical companies can afford compliance. Small and mid cap biotech companies producing rare disease treatments, firms like Japan's Ono Pharmaceutical and Kyowa Kirin or India's Biocon, lack the scale to relocate manufacturing and will face the full 100% tariff. The ITIF projects that this will hit patients directly: commercial insurance patients face the greatest pressure, high deductible plan enrollees are most vulnerable to branded drug pricing increases, and uninsured populations bear the brunt of generic drug price increases if the exemption is lifted.

Streamlining the Facility Approval Pipeline

The FDA Manufacturing PreCheck Pilot Program, which began accepting applications on 1 February 2026, is the first concrete regulatory mechanism designed to reduce the time to market for domestically manufactured drugs. The programme responds directly to Executive Order 14293, "Regulatory Relief to Promote Domestic Production of Critical Medicines."

PreCheck operates in two phases. The first is a Facility Readiness Phase, where selected manufacturers engage with FDA for early technical guidance before a facility is operational. Pre operational reviews assess facility design, equipment specifications, and utility systems. Facility specific Drug Master File submissions allow FDA to evaluate manufacturing elements prior to any product application. This front loads the typically time consuming facility qualification process. The second phase covers Application Submission, where FDA and applicants build on Phase 1 through pre submission meetings, expedited assessment of manufacturing information, and coordinated pre approval inspections designed to resolve issues proactively.

Eligibility is limited to new manufacturing facilities only. Existing facilities, extensions, and modernisation projects are excluded. Facilities must have broken ground by the proposal deadline or be in pre operational development, must intend to manufacture human drugs or biological products, and must commit to actively manufacturing products for at least three years following FDA approval. One facility per request, one request per company.

FDA prioritises facilities producing sterile injectables, large volume parenterals, and drugs on the FDA shortage list. Sites using domestically sourced APIs and key starting materials receive preference, as do facilities utilising modular construction, advanced automation, or continuous manufacturing. By front loading facility reviews, PreCheck could shave 12 to 18 months off the traditional approval timeline. But with only 7 slots in the initial cohort and eligibility limited to new facilities, the near term impact is modest. The programme's real value is as a proof of concept for scaling regulatory streamlining if pharmaceutical investment in U.S. manufacturing materialises at the $480 billion level industry has pledged.

The Computational Formulation Imperative

The tariff order compresses timelines that pharmaceutical technology cannot compress through brute force. You cannot build a factory in 120 days. You cannot run ICH stability studies in 120 days. You cannot complete bioequivalence studies in 120 days. But you can start making informed formulation decisions in 120 days if you have the right tools.

The reshoring wave creates a set of specific, immediate problems for formulation scientists. Every company moving API production to a new domestic facility will need to requalify that API in its existing formulations. Every ANDA holder sourcing a new domestic API supplier will need to demonstrate that the new material produces an equivalent drug product. Every 505(b)(2) applicant affected by the tariff will need to update CMC sections with bridging studies. The volume of this work, across hundreds of products and dozens of pharmaceutical companies, is enormous. The timeline pressure is real.

DeepC’s studies take on the questions this work raises.

• Qualifying a new supplier: ANVISA’s GMP certificates cover 35,000+ inspected manufacturing sites, and the FDA Drug Master File listings name 40,000+ holders, so DeepC can say who is authorised to make an API or excipient, where, and until when.
• Knowing the reference product: The deformulation study reconstructs a marketed product as a best-estimate Q1/Q2 composition, with its dissolution target and DMF sources for every ingredient.
• Adjusting the formulation: The formulation optimization returns up to three variants of an existing formulation, each stating what it gives up for what it gains, with excipient levels kept inside precedented ranges.
• Regulatory pathway: For site transfer supplements under 21 CFR 314.70, the literature review reads the regulations in the eCFR and the precedent across the FDA and EMA documents, and cites both.
• Your own documents: CMC documents, batch records and stability reports uploaded or synced from SharePoint are searched and cited alongside the regulatory sources.

The pharmaceutical marketing around these tariff deals focuses on dollar figures and job creation. The operational reality is that every dollar of pharmaceutical investment in new manufacturing capacity requires a corresponding formulation workstream to ensure the product made in the new facility matches the product made in the old one. The companies that navigate this transition fastest will be those with the best pharmaceutical technology platforms for formulation decision making.